Concepedia

Hepatic Function Dose Adjustment

Hepatic Function Dose Adjustment is a pharmacokinetic dose modification strategy that specifically accounts for impaired liver function by altering chemotherapy dosing regimens to mitigate toxicity risks associated with reduced hepatic metabolic capacity.

22

Publications

1.3K

Citations

149

Authors

51

Institutions

Publications per year

2017–2026

4

Parents

Publications

22

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

Roger K. Verbeeck · European Journal of Clinical Pharmacology · 2008 · 638 citations

, , +14

Etoposide pharmacokinetics in patients with normal and abnormal organ function.

Susan G. Arbuck, H. O. Douglass, W R Crom et al. · Journal of Clinical Oncology · 1986 · 96 citations

, , +17

Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic Function

Séamus O’Reilly, Eric K. Rowinsky, William J. Slichenmyer et al. · JNCI Journal of the National Cancer Institute · 1996 · 74 citations · Full text

, , +17

Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level

Valérie Boige, Mohamed Hebbar, David Malka et al. · European Journal of Cancer · 2006 · 66 citations

, , +17

Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing

Hiteshkumar D Patel, Merrill J. Egorin, S. C. Remick et al. · Journal of Clinical Oncology · 2004 · 59 citations

, , +17

1–5 of 22

Authors

149

  1. SP
    S. Percy Ivy

    National Cancer Institute, United States

    3 publications · 85 citations

    3

    h-index

  2. MJ
    Merrill J. Egorin

    UPMC Hillman Cancer Center, United States

    3 publications · 98 citations

    3

    h-index

  3. JH
    James H. Doroshow

    National Cancer Institute, United States

    2 publications · 116 citations

    2

    h-index

  4. DM
    Daniel Mulkerin

    University of Wisconsin Carbone Cancer Center, United States

    2 publications · 74 citations

    2

    h-index

  5. AJ
    Anthony J. Murgo

    National Cancer Institute, United States

    2 publications · 74 citations

    2

    h-index

1–5 of 149

Institutions

51

  1. The University of Texas at San Antonio Health Science Center

    San Antonio, United States

    4 h-index

    28 publications

    973 citations

  2. City Of Hope National Medical Center

    Duarte, United States

    3 h-index

    21 publications

    797 citations

  3. City of Hope

    Lancaster, United States

    3 h-index

    21 publications

    797 citations

  4. UPMC Hillman Cancer Center

    Pittsburgh, United States

    2 h-index

    20 publications

    740 citations

  5. Case Western Reserve University

    Cleveland, United States

    2 h-index

    20 publications

    740 citations

  6. Lewis Gale Medical Center

    Salem, United States

    1 h-index

    1 publications

    11 citations

  7. Hôpital Claude Huriez

    Lille, France

    1 h-index

    1 publications

    66 citations

  8. University of California, San Francisco

    San Francisco, United States

    1 h-index

    4 publications

    92 citations

1–8 of 51

Venues

  1. Journal of Clinical Oncology

    4 publications · 180 citations

    4

    h-index

  2. PubMed

    Repository · 2 publications · 52 citations

    2

    h-index

  3. The Journal of Clinical Pharmacology

    1 publications · 28 citations

    1

    h-index

  4. 1

    h-index

  5. Cancer

    1 publications · 38 citations

    1

    h-index

1–5